MedStar Health agrees to $35M settlement over claims of unnecessary stent procedures
Columbia-based MedStar Health has agreed to a $35 million settlement with the U.S. Department of Justice over allegations that it paid kickbacks to a local cardiovascular group in return for referrals. The payment will resolve allegations that MedStar made payments to Pikesville, Maryland-based MidAtlantic Cardiovascular Associates in the kickback scheme. The scheme allegedly included lucrative cardiovascular procedures, including cardiac surgery and interventional cardiology procedures, from Ja n.1,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2019 Category: American Health Authors: Ryan Sharrow Source Type: news

MedStar Health agrees to $35M settlement over claims of unnecessary stent procedures
MedStar Health has agreed to a $35 million settlement with the U.S. Department of Justice over allegations that it paid kickbacks to a local cardiovascular group in return for referrals. The payment will resolve allegations that MedStar made payments to Pikesville-based MidAtlantic Cardiovascular Associates in the kickback scheme. The scheme allegedly included lucrative cardiovascular procedures, including cardiac surgery and interventional cardiology procedures, from Jan.1, 2006 to July 31, 2011.  The… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 21, 2019 Category: American Health Authors: Ryan Sharrow Source Type: news

MedStar Health agrees to $35M settlement over claims of unnecessary stent procedures
MedStar Health has agreed to a $35 million settlement with the U.S. Department of Justice over allegations that it paid kickbacks to a local cardiovascular group in return for referrals. The payment will resolve allegations that MedStar made payments to Pikesville-based MidAtlantic Cardiovascular Associates in the kickback scheme. The scheme allegedly included lucrative cardiovascular procedures, including cardiac surgery and interventional cardiology procedures, from Jan.1, 2006 to July 31, 2011.  The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 21, 2019 Category: Biotechnology Authors: Ryan Sharrow Source Type: news

Inhaled, IV Anesthestics Even in Cardiac Surgery Survival
(MedPage Today) -- MYRIAD trial doesn't favor cardioprotection of sevoflurane, similar drugs (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 21, 2019 Category: Cardiology Source Type: news

Women Fare Worse After Thoracic Aortic Surgery Women Fare Worse After Thoracic Aortic Surgery
Older age at surgery for women and surgical repair later in the disease process may contribute to this disparity.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 21, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

ACC 2019: Abbott touts reduced stroke, bleeding and pump-clotting in HeartMate 3 trial
Abbott (NYSE:ABT) yesterday presented data from a new trial of its HeartMate 3 left ventricular assist device, touting a reduced rate of strokes, pump-related blood clots and bleeding episodes at two years as compared with the previous generation HeartMate II. Data in the trial was presented at the American College of Cardiology’s 68th Annual Scientific Session 2019 in New Orleans and published simultaneously in the New England Journal of Medicine, the Chicago-area medical device company said. Abbott touted its HeartMate 3 as the first implantable mechanical pump using fully magnetic levitation technology, makin...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Abbott Source Type: news

ACC 2019: Medtronic, Edwards low-risk TAVR trial data could pave way to new indications
Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology. Data from the trials were presented over the weekend at the American College of Cardiology 68th Annual Scientific Session 2019 in New Orleans and simultaneously published in the New England Journal of Medicine. Currently, TAVR devices are only approved by the FDA for treating severe aortic valve stenosis in patients at ...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves Edwards Lifesciences Medtronic Source Type: news

Daily Aspirin No Longer Recommended To Prevent Heart Attacks In Older Adults
(CNN) — If you’re a healthy older adult looking for ways to reduce your risk of heart attack and stroke, don’t turn to that age-old standby: daily low-dose aspirin. It’s no longer recommended as a preventative for older adults who don’t have a high risk or existing heart disease, according to guidelines announced Sunday by the American College of Cardiology and the American Heart Association. “For the most part, we are now much better at treating risk factors such as hypertension, diabetes and especially high cholesterol,” said North Carolina cardiologist Dr. Kevin Campbell, who wa...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 18, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News aspirin CNN Source Type: news

Low-Risk TAVR at Least as Good as Surgery in Pivotal Trials
(MedPage Today) -- Evolut, PARTNER 3 trials called " game changers " (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 16, 2019 Category: Cardiology Source Type: news

Doing Shoulder Surgery in Denver (or La Paz)? Read This
(MedPage Today) -- 40-fold (!) increase in 30-day pulmonary embolism risk with procedures performed at high altitude (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 15, 2019 Category: Cardiology Source Type: news

Surgery no better than medication at preventing serious complications of atrial fibrillation
(NIH/National Heart, Lung and Blood Institute) Catheter ablation, a common cardiovascular procedure, appears no more effective than drug therapies in preventing strokes, deaths, and other complications in patients with atrial fibrillation. However, patients who get the procedure experience much greater symptom relief and long-term improvements in the quality of life, including fewer recurrences of the condition and fewer hospitalizations, than those who get only drugs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2019 Category: International Medicine & Public Health Source Type: news

Abbott wins expanded indications for MitraClip
The FDA today said that it granted Abbott (NYSE:ABT) a new indication for its MitraClip system, expanding coverage of the device to patients with normal mitral valves with diminished left heart function. The indication expands upon the original approval, which the Chicago-area medical device maker won in 2013, clearing it for use in reducing mitral regurgitation in patients with mitral valve abnormalities whose risks for mitral valve surgery were prohibitive. With its new clearance, the MitraClip is cleared for use for patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or...
Source: Mass Device - March 14, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news

Study: Less-Invasive Mesothelioma Surgery Yields Better Results
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - March 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Corindus Vascular Robotics meets The Street with Q4 earnings
Corindus Vascular Robotics (OTC:CVRS) shares gained today after the robot-assisted surgery company reported fourth-quarter results that met the forecast on Wall Street. Losses grew 3.1% for Waltham, Mass.-based Corindus posted to -$8.2 million, or -4¢ per share, on sales growth of 11.5% to $4.7 million for the three months ended Dec. 31, 2018, compared with the same period in 2017. Analysts were looking for LPS of -4¢. Full-year losses were ip 25.0% to -$42.6 million, or -22¢ per share, on sales growth of 11.7% to $10.8 million compared with 2017. “2019 is poised to be another significant year for Cori...
Source: Mass Device - March 13, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular MassDevice Earnings Roundup Robotics Wall Street Beat Corindus Vascular Robotics Source Type: news

Driving Pressure During Thoracic Surgery Driving Pressure During Thoracic Surgery
How do these ventilation strategies compare in terms of postoperative pulmonary complications after thoracic surgery?Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2019 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Medical News Today: What to know about heart pacemakers
A pacemaker keeps the heart beating regularly, and inserting one into the chest requires surgery. This is a relatively safe procedure. Learn more about heart pacemaker surgery here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 11, 2019 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

How Safe Are Overlapping Surgeries? (CME/CE)
(MedPage Today) -- No ties to significant differences in in-hospital mortality or post-op complication rates, but surgery length was increased (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 5, 2019 Category: Cardiology Source Type: news

Avita says EU sales temporarily interrupted, inks Japanese distro deal for Recell
Avita Medical (ASX:AVH) said yesterday that sales of its Recell device in the European Union were temporarily interrupted due to an administrative issue with its notified body and announced a new Japanese marketing and distribution deal. The Valencia, Calif.-based company said that the sales interruption occurred after its EU-based notified body “reported open items related to administrative and procedural non-conformities,” but said that the action has no impact outside the EU and that issues are not related to product quality, safety or performance. Avita said that it does not actively promote the produc...
Source: Mass Device - March 4, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Featured Regulatory/Compliance Wound Care avitamedical Source Type: news

Belgian EPP Study Shows Mesothelioma Surgery Extends Survival
Using proper patient selection, doctors in Leuven, Belgium, are extending mesothelioma survival times significantly with the controversial extrapleural pneumonectomy surgery. Despite a growing reluctance to perform the surgery within the United States and throughout much of Europe, mesothelioma specialists at University Hospitals KU Leuven have continued performing it with great success. Their 2018 single-center study of the extrapleural pneumonectomy (EPP) for pleural mesothelioma produced a 33.2-month median survival and a 24.2 percent five-year survival. “With our dedicated team, a patient can do well with this su...
Source: Asbestos and Mesothelioma News - March 4, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

VR, AR elevate radiologists' value in future of medicine
How can virtual reality (VR) and augmented reality (AR) help radiologists advance...Read more on AuntMinnie.comRelated Reading: AR aids image-guided spinal procedures on live patients AR improves operative view for robotic thyroid surgery Virtual reality may help plan, guide glioma resection VR, AR may revamp cardiovascular imaging Virtual reality adds depth to brain aneurysm diagnosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 4, 2019 Category: Radiology Source Type: news

Targeting Certain Lymph Nodes Could Change Mesothelioma Treatment
Thoracic surgeon Dr. Joseph Friedberg at the University of Maryland School of Medicine has identified previously underutilized lymph nodes that could change the way pleural mesothelioma is diagnosed, staged and treated. Friedberg is the head of the Division of Thoracic surgery at Maryland and director of the Mesothelioma and Thoracic Oncology Treatment and Research Center. The findings are based upon the posterior intercostal lymph nodes — a part of the lymphatic system between the ribs near the spine — in 56 mesothelioma patients who were part of a recent clinical trial. Friedberg detailed the groundbreaking f...
Source: Asbestos and Mesothelioma News - February 26, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

What Is the Most Common Type of Cardiomyopathy?
Discussion Barth syndrome is characterized by a dilated cardiomyopathy, proximal skeletal muscle weakness, neutropenia and short stature that usually presents at birth or soon after. It is a rare X-linked recessive disease process caused by mutations in the TAZ gene. The TAZ gene codes for tafazzin which alters cardiolipin in mitochondria. Characteristic facies can be seen especially in infancy including a tall and broad forehead, prominent chin and full cheeks, larger ears, and deep-set eyes. Most patients present at birth or soon afterwards but some may not until later in life. Life expectancy is reduced with many childr...
Source: PediatricEducation.org - February 25, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Superior Survival With TEVAR vs Open Aortic Aneurysm Repair Superior Survival With TEVAR vs Open Aortic Aneurysm Repair
Endovascular repair is increasingly used instead of open surgery for descending thoracic aortic aneurysms. Now, a new study suggests that TEVAR should be the standard of care.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 21, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

CorMatrix launches FDA IDE Cor Tricuspid ECM cardiac valve trial
CorMatrix Cardiovascular said today that it launched a trial of its Cor Tricuspid ECM cardiac valve intended for treating adults with endocarditis and pediatric patients with congenital heart valve disease, adding that the first patient in the trial has already been treated. The first procedure in the trial took place at the Francicscan Health Heart Center by a team led by Dr. Marc Gerdisch, Atlanta-based CorMatrix said. The patient, who was suffering from endocarditis, has returned home and is recovering well, the company added. “This first FDA study enrollment is a substantial step toward patients avoiding syn...
Source: Mass Device - February 21, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves CorMatrix Cardiovascular Inc. Source Type: news

More Young Women Are Having Heart Attacks, Study Says. This Could Be Why
Younger women are having more heart attacks, and accounted for nearly a third of all female heart attack patients in recent years, according to a recent study. The news compounds a string of recent findings that have pointed to poorer overall health for young American women. “Women now, compared to younger women generations before them, are less healthy,” says study co-author Melissa Caughey, a cardiovascular epidemiologist and instructor at the University of North Carolina Chapel Hill School of Medicine. “It’s probably reflective of poorer health in general.” The study, which appeared in a sp...
Source: TIME: Health - February 21, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime Research Source Type: news

HF With/Without Symptoms Tied to Higher Death Risk After Surgery (CME/CE)
(MedPage Today) -- Left ventricular function and other factors predict non-cardiac surgical outcomes in patients with heart failure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 20, 2019 Category: Cardiology Source Type: news

IV Acetaminophen May Combat Delirium After Cardiac Surgery
(MedPage Today) -- Older patients also had shorter ICU stays in single-center randomized trial (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 20, 2019 Category: Cardiology Source Type: news

It ’s Time for New Medtech Materials—Could Academia Help?
The medtech industry is mostly still using the same polymers and metallic materials used 60 years ago, says Jeremy J. Harris, Ph.D., director, research, for Secant Group. “There’s been little introduction of new materials,” with the exception of resorbables, he told MD+DI. But “as medical technology advances, such as it is in regenerative medicine and tissue engineering, there’s a greater demand for new materials.” Such insufficiency can result in a “compliance mismatch” between de...
Source: MDDI - February 15, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Materials Source Type: news

Affluent Medical touts results of endovascular aneurysm repair study
Medtech startup Affluent Medical (Paris, France) said a study of its endovascular aneurysm repair (EVAR) system device showed patients had fewer endoleaks and needed fewer secondary interventions, and that their aneurysms shrank in volume and diameter. The company’s Kardiozis endovascular prosthesis uses thrombogenic fibers to embolize an abdominal aortic aneurism sac during a conventional EVAR procedure to prevent endoleaks and the recurrence of the condition. The Scope 1 randomized, controlled, multicentric clinical trial enrolled 102 patients at four sites in France, beginning in 2013. With a 24-month fo...
Source: Mass Device - February 15, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Cardiovascular Clinical Trials Featured News Well Research & Development affluentmedical Source Type: news

Circulatory Support in PCI; TEVAR vs Surgery; Varying Thrombectomy Techniques
(MedPage Today) -- Interventional cardiology news to note (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 14, 2019 Category: Cardiology Source Type: news

IBM Watson Health announces slew of AI-based research partnership deals
IBM Watson Health today announced a number of new partnership deals, including an expanded collaborative deal with the Broad Institute of MIT and Harvard and 10-year, $50 million collaborative research deals with the Brigham and Women’s Hospital and the Vanderbilt University Medical Center. The Cambridge, Mass.-based IBM division said that it inked an extended partnership with the Broad Institute looking to analyze and explore genomics data to better understand the intrinsic possibility individuals have for a certain disease. The newly inked initiative aims to incorporate population-based and hospital-based biob...
Source: Mass Device - February 13, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Software / IT IBM Watson Health Source Type: news

AtriCure launches CryoIce CryoSphere probe
AtriCure (NSDQ:ATRC) today launched its CryoIce CryoSphere probe in the U.S. The Mason, Ohio-based company’s CryoSphere probe is designed to block pain by temporarily ablating peripheral nerves. The device features a bendable distal shaft and an ergonomic handle that enables cardiac, thoracic and general surgeons to easily target peripheral nerves. ArtiCure’s CryoSphere technology uses a freezing method to stop nerves from sending pain signals for several months, giving the patient’s body time to heal. “The addition of the CryoSphere probe to our pain management portfolio is a major breakthroug...
Source: Mass Device - February 12, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Featured Pain Management Wall Street Beat AtriCure Inc. Source Type: news

Transcatheter mitral valve tech dev CardioMech AS raises $3m
Early stage cardiovascular intervention tech developer CardioMech AS said today that it raised $2.5 million in a convertible note financing round. The Oslo-based company said that the round was significantly oversubscribed, and included investments from experienced angel investors. CardioMech is developing a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve, according to the company’s website. The company’s initial tech will focus on high risk patients suffering from severe symptomatic degenerative mitral regurgitation due to props or flail. “This fin...
Source: Mass Device - February 11, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular CardioMech Source Type: news

Long-term stroke risk cut by carotid surgery or stenting
Methods of treating carotid artery disease. (Image from Mayo Clinic.) An international research team who compared the long-term effects of carotid artery surgery and stenting found the risk of stroke “remarkably low” even 10 years later, regardless of the type of procedure. Short-term stroke prevention was found to be better among surgery patients, but stenting technology has improved since these patients were implanted, said the study’s lead author, who predicted that short-term outcomes of stenting could soon match those of surgery. Get the full story on our sister site, Medical Design & O...
Source: Mass Device - February 11, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Cardiovascular Clinical Trials Implants Neurological News Well Research & Development Mayo Clinic universitycollegelondon Source Type: news

For Brain Bleeds,'Gentle' but Thorough Surgery May Boost Outcomes
(MedPage Today) -- MISTIE III trial failed overall but showed functional benefit with extensive clot removal (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 7, 2019 Category: Cardiology Source Type: news

Leviticus Cardio, Jarvik Heart unveil wireless LVAD
Jarvik Heart and Leviticus Cardio yesterday unveiled a new collaborative wirelessly-powered left ventricular assist device and touted its recent first-in-human use. An article on the new heart and its first implantation was recently published in the Journal for Heart and Lung Transplantation, the companies said. The device, dubbed the Fully Implanted Ventricular Assist Device (FIVAD), is based on Coplanar Energy Transfer technology from Leviticus Cardio as well as a heart pump produced by Jarvik Heart, the companies said. The system includes a fully implanted Jarvik 2000 VAD system which is powered wirelessly using both in...
Source: Mass Device - February 7, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Featured Jarvik Heart Leviticus Cardio Source Type: news

Safety board OKs continuation of CytoSorbents endocarditis trial
CytoSorbents (OTC:CTSO) said this week it the Data Safety Monitoring Board of its REMOVE trial gave the company the green light to continue the study after analyzing data from the first 50 patients. The German gov’t-funded randomized, controlled, multi-center 250-patient REMOVE trial, which was launched in late 2017, looked to explore the safety and efficacy of intraoperative CytoSorb in patients with dangerous bacterial heart valve infections during valve replacement surgeries and cardiopulmonary bypass procedures, the Monmouth, N.J.-based company said. The study’s goal is to demonstrate improved hemodyna...
Source: Mass Device - February 6, 2019 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Regulatory/Compliance CytoSorbents Corp. Source Type: news

AtriCure launches CryoIce persistent AF ablation trial
AtriCure (NSDQ:ATRC) said today that it launched a new FDA investigational device exemption cleared trial of its CryoIce system exploring its use in treating persistent atrial fibrillation during concomitant open-chested cardiac surgery. The first patient in the trial has already been treated, the Mason, Ohio-based company said. The initial procedure took place at Takoma Park, Md.’s Washington Adventist Hospital. “Cryothermal energy has been a mainstay of surgical ablation for a long time. The ICE-AFIB IDE trial is the first of its kind designed to assess the safety and sustained effectiveness of cryotherm...
Source: Mass Device - February 5, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Surgical AtriCure Inc. Source Type: news

What's the Right RA Disease Activity Measure for You? What's the Right RA Disease Activity Measure for You?
A conversation with Dr Susan Goodman about the best tools for monitoring RA and the need to highlight cardiovascular disease risk for patients.Hospital for Special Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 5, 2019 Category: Consumer Health News Tags: Rheumatology Expert Interview Source Type: news

Cook Medical wins FDA nod for Zenith aortic dissection repair stent
Cook Medical said today that it won FDA approval for its Zenith Dissection endovascular system intended to treat Type B aortic dissections. The Bloomington, Ind.-based company’s newly cleared system consists of a proximal stent-graft component and bare stent distal component and is intended to prove a less invasive alternative to open surgery for repairing Type B dissections of the descending thoracic aorta. “We’re pleased to provide another minimally invasive option for aortic repair. The approval of this product gives us an opportunity to have a positive impact on the lives of patients with aortic ...
Source: Mass Device - February 4, 2019 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Regulatory/Compliance Stent Grafts Stents Vascular Cook Medical Source Type: news

CHF Solutions inks Indian Aquadex FlexFlow distro deal
CHF Solutions (NSDQ:CHFS) said yesterday that it inked an agreement with Wayinia Lifesciences to distribute its Aquadex FlexFlow system in India. The Eden Prairie, Minn.-based company said that the agreement will expand its sales outreach in Asia and open access to one of the larger population centers in the region. “We continue to expand our presence worldwide and are pleased to extend the reach of our therapy with our Aquadex FlexFlow system into the Indian healthcare centers for patients who are chronically challenged by fluid overload when diuretics have failed. Heart failure is a global issue and there is a...
Source: Mass Device - February 1, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Distribution CHF Solutions Inc. Source Type: news

A New Way to Model the Heart Valve
The mitral valve repair space just got a little less complicated due to research from a team of engineers from The University of Texas at Austin. The group has developed a new noninvasive technique for simulating repairs to the mitral valve, which they say has levels of accuracy reliable enough for use in a clinical setting. The approach involves the use of computational modeling technology that could allow surgeons to provide patient-specific treatments. The engineers outlined their computational modeling technique for imaging mitral valve leaflets in recent issues of the International Journal for Numerical Methods in Bio...
Source: MDDI - February 1, 2019 Category: Medical Devices Authors: MDDI Staff Tags: Cardiovascular Source Type: news

Medtronic Valiant ™ Captivia™ Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients
Medtronic plc (NYSE:MDT) announced new data supporting the long-term durability, safety, and efficacy of the Valiant ™ Captivia™ thoracic stent graft system for the treatment of blunt thoracic aortic injury (BTAI). The presentation by Himanshu J. Patel, M.D., University of Michigan Department of Cardiac Surgery at The Society of Thoracic Surgeons Annual Meeting, was the first and only five-year industry-issued dataset ever reported for patients with aortic transections undergoing thoracic endovascular aortic repair (TEVAR). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 31, 2019 Category: Cardiology Source Type: news

Women Gain in Thoracic Surgery But Lag on Research Front
(MedPage Today) -- Men keep firm grip on STS research presentations (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 31, 2019 Category: American Health Source Type: news

Preventing Postop Delirium After Noncardiac Thoracic Surgery Preventing Postop Delirium After Noncardiac Thoracic Surgery
Is low-dose postoperative haloperidol effective in reducing delirium in individuals undergoing non-cardiac thoracic surgery?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2019 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

Medtronic touts study data for thoracic aortic stent
Medtronic (NYSE:MDT) said that its thoracic stent graft for the treatment of a potentially deadly blunt-force chest injury performed well five years after implantation, according to a new study. The Rescue study of the long-term durability, safety, and efficacy of the Medtronic’s Valiant Captivia thoracic stent graft system for blunt thoracic aortic injury (BTAI) was presented at The Society of Thoracic Surgeons annual meeting in San Diego this week. It was the first five-year, industry-issued dataset ever reported for patients with aortic transections undergoing thoracic endovascular aortic repair (TEVAR)....
Source: Mass Device - January 30, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Clinical Trials News Well Research & Development Stent Grafts Medtronic Society of Thoracic Surgeons Source Type: news

Cue the Fireworks: Cardiac Surgery in July Might Not Be a Killer
(MedPage Today) -- Rookie thoracic surgeons don't appear to worsen outcomes (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 30, 2019 Category: Surgery Source Type: news

Most Female Thoracic Surgeons Report Sexual Harassment on Job
(MedPage Today) -- Survey finds shocking 81% say #UsToo (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 29, 2019 Category: American Health Source Type: news

Blood Conservation Safe, Effective During Heart Surgery
TUESDAY, Jan. 29, 2019 -- Blood conservation via intraoperative autologous donation (IAD) is safe and effective in reducing transfusions during cardiac surgery, according to research presented at the annual meeting of The Society of Thoracic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2019 Category: Pharmaceuticals Source Type: news

J & J ’ s Ethicon touts surgical staplers study
Ethicon’s Echelon Flex GST system [Image courtesy of Ethicon]Johnson & Johnson’ Ethicon business is promoting the results of a head-to-head study between an Ethicon surgical stapler and a Medtronic stapler system. Ethicon’s Echelon Flex GST system had a 20% staple-line air leak rate when tested out on pig lungs under modeled physiologic breathing conditions, versus a 44% rate for Medtronic’s Endo Gia with Tri-Staple technology. Ethicon funded the research, which is being announced this week at the 2019 Society of Thoracic Surgeons annual meeting in San Diego. Get the full story on our siste...
Source: Mass Device - January 28, 2019 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News News Well Surgical Ethicon johnsonandjohnson Medtronic Source Type: news